Evidence map›Paper›PMID 17596302›Full record

ArticleJournal of virology2007

De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.

Jianjiang Ye, Lyndle Gradoville, Derek Daigle, George Miller

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Arginine Metabolism SupportsbioRxiv : the preprint server for biology · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Role of RNF4 in the ubiquitination of Rta of Epstein-Barr virus.The Journal of biological chemistry · 2013
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jianjiang YeDepartment of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Lyndle Gradoville
Derek Daigle
George Miller
Pediatrics and Genetics · USYale University · US

Funding

VIRAL SMALL RNPS--ROLES IN CELL TRANSFORMATIONP01CA016038 · NCI · YALE UNIVERSITY · PI DIMAIO, DANIEL C. · 1985 to 2020
$25.6M
STUDIES OF EPSTEIN-BARR VIRUSR37CA012055 · NCI · YALE UNIVERSITY · PI MILLER, I. GEORGE · 1989 to 2012
$4.4M
STUDIES OF EPSTEIN-BARR VIRUSR01CA012055 · NCI · YALE UNIVERSITY · PI MILLER, I. GEORGE · 1985 to 2002
$737k
NCI NIH HHS CA12055NCI NIH HHS CA16038NCI NIH HHS P01 CA016038NCI NIH HHS R01 CA012055NCI NIH HHS R37 CA012055
6 · The paper itself

Abstract

The oncogenic human gammaherpesviruses, Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), are latent in cultured lymphoma cells. We asked whether reactivation from latency of either virus requires de novo protein synthesis. Using Northern blotting and quantitative reverse transcriptase PCR, we measured the kinetics of expression of the lytic cycle activator genes and determined whether abundance of mRNAs encoding these genes from either virus was reduced by treatment with cycloheximide (CHX), an inhibitor of protein synthesis. CHX blocked expression of mRNAs of EBV BZLF1 and BRLF1, the two EBV lytic cycle activator genes, when HH514-16 Burkitt lymphoma cells were treated with histone deacetylase (HDAC) inhibitors, sodium butyrate or trichostatin A, or a DNA methyltransferase inhibitor, 5-Aza-2'-deoxycytidine. CHX also inhibited EBV lytic cycle activation in B95-8 marmoset lymphoblastoid cells by phorbol ester phorbol-12-myristate-13-acetate (TPA). EBV lytic cycle induction became resistant to CHX between 4 and 6 h after application of the inducing stimulus. KSHV lytic cycle activation, as assessed by ORF50 mRNA expression, was rapidly induced by the HDAC inhibitors, sodium butyrate and trichostatin A, in HH-B2 primary effusion lymphoma cells. In HH-B2 cells, CHX did not inhibit, but enhanced, expression of the KSHV lytic cycle activator gene, ORF50. In BC-1, a primary effusion lymphoma cell line that is dually infected with EBV and KSHV, CHX blocked EBV BRLF1 lytic gene expression induced by TPA and sodium butyrate; KSHV ORF50 mRNA induced simultaneously in the same cells by the same inducing stimuli was resistant to CHX. The experiments show, for the cell lines and inducing agents studied, that the EBV BZLF1 and BRLF1 genes do not behave with "immediate-early" kinetics upon reactivation from latency. KSHV ORF50 is a true "immediate-early" gene. Our results indicate that the mechanism by which HDAC inhibitors and TPA induce lytic cycle gene expression of the two viruses differs and suggest that EBV but not KSHV requires one or more proteins to be newly synthesized between 4 and 6 h after application of an inducing stimulus.

Indexed as

Histone Deacetylase InhibitorsProtein BiosynthesisAzacitidineBlotting, NorthernCell LineCycloheximideDecitabineDNA-Binding ProteinsEnzyme InhibitorsGene ExpressionHerpesvirus 4, HumanHerpesvirus 8, HumanHumansHydroxamic AcidsImmediate-Early ProteinsProtein Kinase CAzacitidineBRLF1 protein, Human herpesvirus 4BZLF1 protein, Herpesvirus 4, HumanCycloheximideDecitabineDNA-Binding ProteinsEnzyme InhibitorsHistone Deacetylase InhibitorsHydroxamic AcidsImmediate-Early Proteinsphorbolol myristate acetateProtein Kinase CProtein Synthesis InhibitorsRNA, MessengerRNA, ViralRta protein, Human herpesvirus 8Tetradecanoylphorbol AcetateTrans-Activatorstrichostatin AViral Proteins

Identifiers

PMID17596302
PMCPMC1951462
OpenAlexW2120573006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.